Newsletter Volume 36, Number 1, 2021

Newsletter Volume 36, Number 1, 2021


 Last year was a year that began and ended with coronaviruses. At our university, we have been experimenting with new methods with our students under the idea that “now is the time to never stop research and education” in the midst of restrictions aimed at preventing infection. Most of the lectures were given online. In a subsequent student survey, we received mostly positive feedback about online courses. Therefore, it was decided that from the next academic year, the standard will be a hybrid format in which lectures are given in person (in real life) while students who are unable to come to the university can take the lectures online. Outside of the university, there were also a few positive discussions about the Corona Disaster, although they were few in number. Not only was teleworking implemented nationwide, but in my own city, tablets were distributed to all elementary school students and the use of IoT blocks (programming materials) was started. The flow of people has also been restrained, and the number of vehicles has been reduced. There have also been reports of cities that have returned to blue skies and starry skies due to a marked reduction in air pollution caused by the reduced flow of people and decreased use of cars. As we continue to adapt to the New Normal, we must remain vigilant in reducing the risk of infection, as some prefectures continue to declare a state of emergency. We hope that you will continue to support us in 2021, and we would appreciate your comments and suggestions to the Editorial Board. (T.H.)


Introduction of Feature Articles


 With the development of new discoveries and methods, the evaluation items and methods of pharmaceuticals and other products from R&D to post-marketing evaluation are constantly evolving. Correspondingly, regulatory information from regulatory authorities in Japan, the U.S., and Europe, as well as ICH and other regulatory bodies, is constantly updated. Here, we will introduce the latest technologies and findings used in drug development, regulatory information on drug review, and related information topics. We hope that you will find this article useful for your work.


 NEW FACE – NEW POWER” is intended to provide an opportunity for our members to get to know new and young doctors who are expected to be very active in the future, regardless of industry or academia, and to bring new vitality and stimulation to our society. We would like to ask the authors to introduce themselves, including their personal history, and to write frankly and actively about their research prospects, expectations and suggestions for the society and our field. All of you are expected to be stars of hope for the future of pharmacokinetics and pharmacodynamics. We hope that this corner will foster a “culture of fostering new young power throughout the society” and help the mutual development of old and new members. Please send your suggestions for articles to the editorial board members.